AKT1 and lung carcinoma: Vorinostat can enhance the therapeutic potential of erlotinib in lung cancer cells (Alqosaibi et al. 2022); the combination of MK-2206 and erlotinib can synergistically inhibit the cell proliferation of human cancer cell lines (Hirai et al. 2010); PI3K/Akt/mTOR signaling is the main mechanism of EGFR resistance, and dactolisib is a dual PI3K/mTOR inhibitor (Wu et al. 2019), which may explain the synergy effect of erlotinib and dactolisib.